Overview
Infertility, which is defined as the inability to conceive after 12 months of regular unprotected sexual intercourse, is a common public health concern worldwide. Globally, 9% of reproductive-aged women, including nearly 1.5 million women in the United States, are infertile. 1, 2 The burden of infertility is inordinately higher among women in developing countries; in some regions of south and central Asia, subSaharan and northern Africa, the Middle East, and eastern Europe, infertility rates can reach up to 30% in reproductive-aged women. 3 The inability to conceive not only creates a considerable cost burden for patients and the health care system but is also a major psychological stressor for millions of couples. 4 In many areas of the world, especially in low-and middle-income countries where having biological children is highly valued and expected of couples, involuntary infertility can lead to stigmatization, economic deprivation, social isolation and loss of status, public shame and humiliation, and in some cases, violence. 5, 6 Female infertility may be attributed to a number of factors, typically divided into endocrine, vaginal, cervical, uterine, tubal, and pelvicperitoneal factors, and although estimates vary, approximately 15-30% of cases still remain unexplained. 7 Further insight into the causes of infertility is necessary to help alleviate this multifactorial burden on society.
Tubal factor infertility (TFI) ranks among the most common causes of infertility, accounting for 30% of female infertility in the United States, and is even more prevalent in certain communities. 8 Paralleling the aforementioned global infertility disparity, TFI is disproportionately common in women in developing countries; for example, it has been shown to account for >85% of female infertility cases in regions of subSaharan Africa, compared to 33% of cases worldwide. 3 Most cases of TFI are due to salpingitis, an inflammation of the epithelial surfaces of the fallopian tubes, and subsequent pelvic-peritoneal adhesions, both of which are most commonly caused by previous or persistent infections. 9, 10 Bacteria ascend along mucosal surfaces from the cervix to the endometrium and ultimately to the fallopian tubes. This causal pathway presents itself clinically as acute pelvic inflammatory disease (PID), which in turn is strongly associated with subsequent TFI. In fact, approximately 15% of women with PID develop TFI, and the number of episodes of PID a woman experiences is directly proportional to her risk of infertility. 11, 12 However, the majority of women with TFI do not have a history of clinically diagnosed acute PID, but rather develop asymptomatic or minimally symptomatic salpingitis as a result of upper genital tract infection. 9, 13 Examining the effect of those infections, particularly those that occur in the absence of clinically evident PID, is critical to understanding TFI.
Several sexually transmitted diseases (STDs), including Chlamydia trachomatis and Neisseria gonorrhoeae, have been widely studied to understand their role in salpingitis and infertility. Additionally, several other pathogens such as Mycoplasma genitalium, Trichomonas vaginalis, and other microorganisms within the vaginal microbiome, may also play roles in tubal damage and other potential causes of infertility. Still, data suggest that not all infections yield the same long-term sequelae. The roles of different STD pathogens, co-infections, and interactions with host characteristics, including their individual vaginal microbiome, may all affect a woman's subsequent ability to conceive. While screening and treatment efforts for C trachomatis and N gonorrhoeae have been developed to reduce the incidence of PID and subsequent TFI, additional data are needed to determine the role of other potential pathogens and whether early detection can prevent tubal damage. In this article, we discuss the pathogens C trachomatis, N gonorrhoeae, Mycoplasma genitalium, T vaginalis, and other potential organisms that may affect female fertility, and we address the clinical importance of screening and preventing the spread of those infections.
Methodology
We conducted a comprehensive literature search to identify articles by using the electronic databases MEDLINE, Embase, Web of Science, and CINAHL, in addition to scrutinizing references of identified articles. Within each database, we combined the term "female infertility" with 4 different infection terms: "Chlamydia trachomatis," "Neisseria gonorrhoeae," "Mycoplasma genitalium," and "Trichomonas vaginalis." Within the MEDLINE database, we refined the search by excluding the Medical Subject Headings unrelated to female infertility and at least 1 of the 4 organisms. Within the Embase search, we used Emtree to identify terms, and used both "female infertility" and "uterine tube occlusion" as focused search terms to combine with each infection. We filtered results to only include articles published in English between 1975 and April 2016. Additional relevant articles were identified from bibliographies and by the recommendation of medical experts. The inclusion of the articles used in the analysis was based on quality of the study and relevance to this review: studies were excluded if they were conducted with few participants, had no comparison group, or constituted case reports. Studies that did not report sufficient data to determine the association with female infertility or reproductive morbidities were excluded for lack of relevance to the topic of review.
C trachomatis and N gonorrhoeae C trachomatis and N gonorrhoeae have been extensively shown to be associated with infertility, particularly by causing tubal inflammation. In fact, early speculation regarding the effect of N gonorrhoeae on female fertility dates back to the 1870s, when the German-born gynecologist Emil Noeggerath published his revolutionary claims about gonorrhea as a clinical condition in his book Latent Gonorrhoea Especially with Regard to its Influence on Fertility in Women.
14 Although he may have widely overestimated its repercussions (postulating that gonorrhea causes 90% of female infertility), his theories eventually sparked the initiation of further investigations. 15 When the bacterium N gonorrhoeae was finally isolated, Noeggerath's controversial claims regarding the persistence of this "venereal poison" in the reproductive organs and its pathologic consequences were reexamined. 16 Studies conducted more than a century later have since demonstrated the impact of C trachomatis and N gonorrhoeae on subsequent infertility.
C trachomatis, the most common reportable disease in the United States, affects nearly 1.5 million people in the US annually. 17 Unfortunately, however, because C trachomatis infections are asymptomatic in most women, 18, 19 infections are often unnoticed, untreated, and underreported. For almost 40 years, evidence has shown that untreated ascending C trachomatis infection can lead to irrevocable damage in the fallopian tubes including proximal and distal tubal occlusions leading to infertility. 9 The increased amount of heat shock protein synthesized by C trachomatis induces a proinflammatory immune response in the human fallopian tube epithelia, resulting in scarring and tubal occlusion. 9, 20, 21 A number of seroepidemiological studies have examined the prevalence of antibodies to C trachomatis and chlamydial heat shock protein in women with laparoscopically or hysterosalpingographically confirmed fallopian tube damage and ectopic pregnancies. [22] [23] [24] [25] [26] [27] [28] The results of these studies indicate that history of C trachomatis infection is associated with a significantly increased risk of tubal infertility in women, regardless of the infection invoking clinical symptoms. 20, 25, [29] [30] [31] [32] Extensive research has also shown that C trachomatis infection can cause PID, which often precedes infertility. Today, C trachomatis accounts for approximately 50% of cases of acute PID in developed countries. 33 Among PID patients, those with prior C trachomatis infection have been shown to be more likely to experience subsequent infertility than those without a history of C trachomatis infection. [32] [33] [34] [35] While C trachomatis seropositivity has long been shown to influence fallopian tube patency, 36 the use of a newer, more sensitive and specific antichlamydial assay by Geisler and coworkers 37 has only recently been shown to hold promise as a measure of tubal function. 38 In a cohort study of 1250 infertile women with documented tubal patency undergoing fertility treatment, C trachomatis seropositivity using the antibody subclasses IgG1 and IgG3 was tested. 39 Results showed that of these 2 antibody subclasses tested, seropositivity to C trachomatis based on IgG3 detection was a strong predictor of both failure to conceive and ectopic pregnancy outcomes. Because IgG3 has been shown to be involved in early inflammatory response to infection, 40 the detection of IgG3 in these women may reflect a recently cleared or persistent C trachomatis infection, contributing to fallopian tube damage while perhaps not yet leading to blockage of the fallopian tubes. 39 In another study of subfertile women with no visible tubal pathology, positive chlamydial antibody testing was associated with a 33% lower spontaneous pregnancy rate than those without chlamydial antibodies. 28, 39 Coppus and colleagues 28 suggest that these low pregnancy rates may not only be caused by the known mechanism of chronic inflammatory response causing fallopian tube damage; persistent C trachomatis infections have also been shown to elicit an autoimmune response to human heat shock proteins, which may elevate the risk for impaired embryo development Expert Reviews ajog.org and implantation. 41, 42 Chlamydial antibody testing may therefore continue to become a valuable predictor of not only tubal patency, but also of ectopic pregnancy, intrauterine insemination failure, and embryo and pregnancy wastage, independent of tubal damage.
Although less prevalent than C trachomatis in the United States, gonorrhea is still the second most common reportable disease in the United States. 17 N gonorrhoeae infections are also often asymptomatic among women, but as Noeggerath suspected in the 1870s, 14 the bacterium is capable of ascending to the upper genital tract and causing severe reproductive morbidities. In particular, N gonorrhoeae attacks the epithelial cells of the fallopian tube, both initially by attaching to the nonciliated mucosal cells and by sloughing off ciliated mucosal cells. 9 The resulting damage hinders the fallopian tubes' ability to transport the ovum for fertilization within the tubes and implantation in the uterus, thus ultimately elevating the risk of infertility and ectopic pregnancy.
Several seroepidemiological studies have demonstrated the pathogen's effects on fallopian tube damage and subsequent infertility. [43] [44] [45] [46] [47] Throughout those studies, women with laparoscopically and hysterosalpingographically confirmed TFI have consistently demonstrated a significantly higher prevalence of serologically confirmed N gonorrhoeae infection than women with normal fallopian tubes. Like chlamydial PID, gonococcal PID has been shown to be an important cause of fallopian tube damage, greatly increasing a woman's risk of TFI. Between 10-19% of women with cervical N gonorrhoeae infections have clinical signs of acute PID 48 and in regions of the United States that had high endemic rates of gonorrhea during the 1970s and 1980s, gonorrhea was found in >40-50% of patients with PID. 49 In recent studies, the bacteria were identified in approximately 20% of women diagnosed with acute PID, suggesting that N gonorrhoeae is not as frequent a cause of acute PID as it was in the past.
50,51 Still, the impact of both chlamydial and gonococcal infections on the fallopian tubes currently make these pathogens the most important known preventable causes of infertility, and improving screening programs for these prevalent and commonly asymptomatic pathogens may therefore make a critical impact in the prevention of tubal pathology and infertility.
Mycoplasma genitalium
While N gonorrhoeae and C trachomatis are known to be pathogens in salpingitis and tubal infertility, in many cases, neither organism is identified. 50 Mycoplasma genitalium, a member of the Mollicutes class with the smallest known genome of any free-living organism, 52 was discovered in 1981 when it was first isolated from men with nongonococcal urethritis. 53 After the development of nucleic acid amplification assays in the early 1990s facilitating its detection, Mycoplasma genitalium has since been shown to be a common sexually transmitted organism. 54 In 2007, the United States prevalence of Mycoplasma genitalium in young adults was 1%, placing it between the prevalences of N gonorrhoeae (0.4%) and C trachomatis (2.3%) infections, and it has been detected in 15-20% of high-risk, sexually active women in the United States. [55] [56] [57] Since its discovery, numerous studies demonstrate that Mycoplasma genitalium is strongly associated with male urethritis. In an analysis of 34 studies published from 1993 through 2011 studying men with nongonococcal urethritis, 13% of 7123 men tested positive for Mycoplasma genitalium, and several studies have demonstrated that Mycoplasma genitalium can cause persistent or recurrent urethritis. 58 After the initial findings of Mycoplasma genitalium demonstrating its effects in males, investigators soon began to look at its effects on the female reproductive tract. While there are fewer studies in women, Mycoplasma genitalium has been investigated to evaluate its association with several morbidities in women, including cervicitis, urethritis, PID, ectopic pregnancy, and TFI. 58 Four serological studies have investigated the relationship between past Mycoplasma genitalium infection in women and tubal infertility. 23 ,24, 59, 60 Two of those studies demonstrated a significant correlation between presence of antibodies against Mycoplasma genitalium and laparoscopically confirmed TFI, independent of C trachomatis seropositivity. 23, 24 According to Svenstrup and colleagues, 24 among women with TFI, 23% had antibodies to C trachomatis and 17% to Mycoplasma genitalium; whereas 15% and 4% of infertile women with normal fallopian tubes had antibodies to each, respectively. Although not quite as high as the prevalence of antibodies to C trachomatis, prior Mycoplasma genitalium infection is thought to be an independent risk factor for TFI. In a similar study by Clausen and colleagues, 23 serological analyses of women with TFI reinforced the finding that Mycoplasma genitalium is independently associated with tubal inflammation leading to infertility. 23 A more recent study by Idahl and colleagues 59 examined the association between Mycoplasma genitalium antibodies and infertility in 239 women diagnosed with infertility of various causes, including laparoscopically and hysterosalpingographically confirmed TFI, compared to 244 fertile controls. The results indicate that Mycoplasma genitalium serum antibodies are more common among women with all causes of infertility (5.4%) than in fertile controls (1.6%). Among the infertile women in that sample diagnosed specifically with TFI, 9.1% were seropositive for Mycoplasma genitalium compared with 4.6% of the fertile controls, although the association between TFI and Mycoplasma genitalium was not statistically significant after adjusting for C trachomatis seropositivity. 59 Supporting evidence has shown an association between infection with Mycoplasma genitalium at the time of infertility evaluation and laparoscopically confirmed tubal infertility, rather than serologically investigating infection history. In a study comparing infertile and fertile women by polymerase chain reaction testing of cervical samples, Mycoplasma genitalium was detected more frequently in infertile women (19.6%) compared to fertile women (4.4%). 61 However, in the study by ajog.org Expert Reviews
Svenstrup and colleagues 24 that examined the relationship between Mycoplasma genitalium seropositivity and TFI, none of the women had a cervical swab specimen indicating current Mycoplasma genitalium infection, and only 62, 63 demonstrated that the organism can attach to reproductive tract epithelial cells and elicits cellular immune responses that result in inflammation. In another in vitro organ culture model, Mycoplasma genitalium adhered to human fallopian tube epithelium after experimental inoculation, causing swelling of the cilia and detachment of cilia from the epithelium. 64 Svenstrup and colleagues 65 also investigated whether mobile sperm could serve as a vector for transmitting Mycoplasma genitalium to the upper genital tract of women, demonstrating that the organism does adhere to human spermatozoa and could be transported by sperm to the uterus and fallopian tubes to colonize and destroy the ciliated epithelia.
When compared with the more severe damage that C trachomatis and N gonorrhoeae infection create in the fallopian tube, the damage caused by Mycoplasma genitalium tends to be moderate. 62 However, when left untreated, damage may accumulate and yield serious longterm sequelae on fallopian tube function. Additionally, simultaneous infection with Mycoplasma genitalium and other sexually transmitted bacteria may cause even more severe tubal pathology. One study conducted in Saudi Arabia used polymerase chain reaction performed on tubal samples from women with ectopic pregnancy and compared them to samples from fertile women undergoing partial salpingectomy for sterilization or at the time of hysterectomy. 66 They found a 6-fold higher rate of infection with C trachomatis and Mycoplasma genitalium in women with ectopic pregnancy compared to the controls. There was also a higher rate of other infections, including Ureaplasma urealyticum/U parvum, Gardnerella vaginalis, N gonorrhoeae, and T vaginalis, but these associations were not statistically significant. The investigators noted that co-infection with at least 2 organisms led to a 5-fold increase in the risk of ectopic pregnancy, providing further evidence that multiple infections lead to greater risk of tubal damage. 66 Animal studies have also been performed to investigate the potential role of Mycoplasma genitalium on tubal scarring and inflammation. Female grivet monkeys and marmosets inoculated with Mycoplasma genitalium developed severe endosalpingitis, along with luminal exudates and adhesions between mucosal folds in the fallopian tubes, similar to changes induced by chlamydial infection. 67 Additionally, female Swiss Webster mice developed upper reproductive tract infection as early as 3 days after being inoculated with Mycoplasma genitalium, showing experimentally that Mycoplasma genitalium is capable not only of ascending through the upper genital tract, but persistently colonizing reproductive tract tissues that could lead to long-term tubal inflammation and occlusion. 68 Both serological and epidemiological studies have explored whether Mycoplasma genitalium is associated with clinical PID and salpingitis. In an analysis of 193 patients with clinically diagnosed PID and 246 healthy pregnant controls, 17% were Mycoplasma genitalium seropositive, although the association was not statistically significant after adjusting for age and presence of antibodies to C trachomatis. 69 An older study by Møller and colleagues 70 also showed an association; in a group of patients with acute PID without C trachomatis antibodies, almost 40% had a 4-fold change in the titre of Mycoplasma genitalium antibodies. Still, results are conflicting, as Lind and Kristensen 71 assessed the significance of antibodies to Mycoplasma genitalium in patients with acute salpingitis and failed to confirm any association.
Recent studies have examined the relationship between current cervical or endometrial Mycoplasma genitalium infection and upper genital tract infection. [71] [72] [73] [74] [75] In an analysis of 586 women who participated in the PID Evaluation and Clinical Health (PEACH) Study, a randomized multicenter clinical trial in the United States, 31% of women who tested positive for Mycoplasma genitalium in the endometrium reported recurrent PID, 42% had chronic pelvic pain, and 22% were infertile. 72 However, a large prospective trial of 2378 young women in London failed to show an association between Mycoplasma genitalium and acute PID. Among women with Mycoplasma genitalium at baseline, 3.9% developed PID after 12 months compared with 1.7% of women without baseline infection; however, this difference was not statistically significant. 63 Oakeshott and colleagues 76 concluded that because the population attributable risk of PID due to Mycoplasma genitalium was only 4%, Mycoplasma genitalium infection is not an important risk factor for pelvic inflammation. This particular European population may not be generalizable to populations with higher prevalence rates of Mycoplasma genitalium infection, where, if confirmed, this 2-fold increased risk of PID due to Mycoplasma genitalium infection could constitute a major public health problem. 72 Still, while evidence shows that Mycoplasma genitalium is often present in or associated with PID cases, 77 more data are necessary to determine the role of this microorganism in the pathogenesis of PID and subsequent TFI.
Mycoplasma genitalium may not only affect tubal patency; several studies have investigated its effects on pregnancy outcomes such as ectopic pregnancy, recurrent pregnancy loss, and preterm birth. However, unlike for C trachomatis, there is limited evidence that the pathogen is associated with these adverse pregnancy outcomes. A serological Expert Reviews ajog.org case-control study by Jurstrand and coworkers 69 showed no significant correlation between Mycoplasma genitalium antibodies and ectopic pregnancy. According to a recent meta-analysis, Mycoplasma genitalium infection has been shown to be significantly associated with increased risk of both spontaneous abortion and preterm birth in some studies, although evidence is inconsistent. 77 While data are emerging on the impact of Mycoplasma genitalium on the reproductive health of women, further research is necessary to solidify any conclusions regarding Mycoplasma genitalium and adverse pregnancy outcomes.
T vaginalis
Like that of Mycoplasma genitalium, the role of T vaginalis infection in reproductive tract pathology has been understudied, but investigators have shown that it may be associated with female infertility. T vaginalis is the most common nonviral sexually transmitted pathogen in the United States. According to the World Health Organization, the protozoan T vaginalis accounts for more than half of all curable STDs worldwide. 78 An estimated 7.4 million new infections occur annually in the United States 79 and approximately 3.1% of reproductive-age women are infected. 80 Given the high prevalence of T vaginalis in the population, any potential impact of the organism on the upper reproductive tract could constitute a serious public health concern.
Data associating T vaginalis with TFI and pelvic inflammation in the literature are relatively weak. Few retrospective studies have found that women with self-reported infertility were 2-3 times more likely to have a current T vaginalis infection, and women with a self-reported history of a T vaginalis infection have approximately a 2-fold risk of tubal infertility. 44, [80] [81] [82] [83] [84] Additionally, a trend exists between increasing number of episodes of T vaginalis infection and increasing risk of infertility. 44 However, many of the epidemiologic studies analyzing the association between trichomoniasis and infertility failed to control for important confounding variables such as presence or history of other reproductive tract infections.
Upon investigation of endometrial inflammatory changes elicited by infections, immunohistochemical evidence shows that T vaginalis may contribute to upper genital tract inflammation. 85 Pathologically, T vaginalis has been shown to be capable of ascending the upper genital tract and has been associated with up to 30% of acute salpingitis cases, although within the same study, trichomonads were not demonstrated in tubal cultures from cases of salpingitis. 86 T vaginalis has been shown to be associated clinically with endometritis, salpingitis, and atypical PID, [87] [88] [89] [90] demonstrating that it may be an important pathogen in upper genital tract damage. Other potential mechanisms linking T vaginalis infection to infertility include disruption of sperm motility, 89 phagocytosis of sperm, and transportation of other infectious agents to the upper genital tract by motile trichomonads, 82, 83 although these mechanisms do not directly affect the female reproductive tract.
Co-infection of T vaginalis and C trachomatis may increase the risk of upper genital tract infection more than the risk of C trachomatis infection alone, and women with both T vaginalis and HIV-1 have been shown to have a significantly higher risk of PID than women without T vaginalis. 83, 90 Because trichomonads are capable of phagocytizing bacteria, yeast, vaginal epithelial cells, mycoplasmas, and herpesviruses in vitro, [91] [92] [93] [94] investigators speculate that T vaginalis infection may be capable of spreading other pathogens throughout the upper genital tract, thereby indirectly eliciting tubal damage and infertility. Moreover, despite some of these weak associations, proposed mechanisms, and possible coinfection risks, there is currently no strong conclusive evidence regarding the causative effects of T vaginalis on PID or infertility.
Vaginal microbiome and other potential pathogens N gonorrhoeae, C trachomatis, and Mycoplasma genitalium may not be the only organisms capable of damaging the reproductive tract. Both Mycoplasma hominis and U urealyticum, 2 common species of genital mycoplasma, have been investigated as possible causative agents for infertility and pelvic inflammation. Mycoplasma hominis is commonly found in the upper genital tract. The adverse influence of Mycoplasma hominis on the female reproductive tract was identified in 1976 by Mårdh and colleagues, 95 as they demonstrated with in vitro organ cultures the swelling of the ciliated tubal epithelial cells due to Mycoplasma hominis infection. The organism has been isolated from the fallopian tubes of women with a history of infertility and laparoscopically confirmed salpingitis, although recent data have not necessarily reproduced these findings. 60, 86, 96, 97 Ureaplasmas, including U urealyticum, have also been investigated as potential culprits of female infertility. Like Mycoplasma hominis, ureaplasmas have been isolated from the fallopian tubes of patients with PID, yet their presence in patients with PID is rare. 86, 98 Some studies suggest a causal relationship between U urealyticum and infertility, but most controlled studies do not confirm such a pathogenic role. Evidence supporting both Mycoplasma hominis and U urealyticum as agents involved in infertility is not nearly as conclusive as existing evidence for pathogens such as C trachomatis and N gonorrhoeae; while some investigators have been able to detect each of the organisms in infertile patients and in patients with upper genital tract disorders, several have not shown any correlation. [98] [99] [100] [101] As with T vaginalis, the existing evidence for Mycoplasma hominis and ureaplasmas as pathogens causing infertility is therefore not sufficiently definitive.
While the focus of this review was to identify sexually transmitted pathogens that affect fertility, other infectious diseases are important to consider in discussing infertility. In the developing world where exposure to Mycobacterium tuberculosis is common, genital tuberculosis (GTB) is a significant cause of infertility. Although its incidence is <1% in industrialized countries, GTB rates ajog.org Expert Reviews can be as high as 13% in developing countries, eliciting a major public health concern. 102 In almost all cases of GTB, Mycobacterium tuberculosis spreads hematogenously from a primary source, most commonly the lungs, to the fallopian tubes, producing irreversible tubal damage and ultimately leading to TFI in up to 40% of cases. 102 In addition to infertility, GTB has also been shown to be an important risk factor for ectopic pregnancy in developing countries. 103, 104 The silent nature of GTB, which often persists without any clinical manifestations, allows development of fulminating infection without detection. 105 Early detection and treatment of GTB is vital to improve reproductive outcomes, but unfortunately provides no benefit to reverse tubal damage once the disease is advanced. 106 Rather than a single organism impairing female fertility, variations in the overall vaginal microbiome, such as in bacterial vaginosis (BV), may also have a role in infertility. 107 A recent meta-analysis exploring the role of BVon infertility has shown that BV is significantly more prevalent in infertile women than in pregnant women of the same population.
108 According to this systematic review of 12 studies reporting the prevalence of BV in patients with infertility of all subtypes, an estimated 1 in 5 infertile women has BV, and at least 1 in 3 has an abnormal vaginal microflora. Four studies have shown that BV is significantly more prevalent in women with tubal infertility than in women with nontubal infertility, [109] [110] [111] [112] including a recent study among Nigerian women that demonstrated that BV was 4 times more prevalent in women with TFI compared to fertile controls. 112 Additionally, after adjusting for several factors, including current infection with N gonorrhoeae, C trachomatis, or T vaginalis, BV has been linked to laparoscopically confirmed PID, endometritis, and salpingitis, 109, [113] [114] [115] [116] suggesting that the effects of BV are not confined to the lower genital tract and may therefore interfere with female fertility. In fact, microorganisms that are highly prevalent in the vagina among women with BV have been recovered in the fallopian tubes of women with laparoscopically confirmed PID and acute salpingitis. 117 However, the role of BV in infertility and in upper genital tract morbidity is still not completely clear, as other studies refute any significant correlation. 118 Likewise, the studies that do show correlations between BV and tubal pathology do not necessarily help distinguish whether this finding is secondary to previous tubal damage caused by infections such as C trachomatis and N gonorrhoeae, or whether BV infection may help spread these infections to the upper genital tract.
111 It is uncertain whether or not BV itself is the direct cause of damage on the fallopian tubes, but given its high prevalence among women with TFI, alongside the high percentage of women with BV that remain undiagnosed and untreated, further investigations elucidating the role of anaerobic overgrowth, biofilms, and the vaginal microbiome are needed. 112 
Conclusions
In summary, the totality of the evidence linking N gonorrhoeae and C trachomatis to infertility is compelling. However, the associations found among Mycoplasma genitalium, T vaginalis, and other potential pathogens are suggestive, but far from definitive. Additional research is necessary to strengthen the suggestions that Mycoplasma genitalium and T vaginalis can cause infertility. We would recommend additional serological studies in a diverse sample of reproductive-aged women while controlling for the history of other STDs. Prospective studies assessing demographic and behavioral factors, the impacts of co-infections, and the impact of the vaginal microbiome are needed to sort out the relationship between these pathogens and impaired fertility and adverse pregnancy outcomes.
Nonetheless, for those pathogens where reproductive tract pathology is evident, screening and treatment should be emphasized in the clinical setting. The literature regarding the importance and benefit of treating these pathogens to enhance fertility on the population level is sparse, although a recent study in Washington observed a potential association between disease management trends and reduction of reproductive morbidities. 57 While further investigations are necessary to establish a tangible benefit, it is nonetheless well understood that women who delay seeking care for what is often an asymptomatic infection have a higher risk for infertility and other reproductive morbidities. The US Preventive Services Task Force has issued chlamydia and gonorrhea screening recommendations since 2000 to reduce associated morbidities, 119 but such guidelines regarding other nontraditional pathogens have not been established. Future research to evaluate the impact of screening and treatment programs for nontraditional pathogens such as Mycoplasma genitalium and other organisms in the microbiome should be considered to help guide clinical practice and health policy to more effectively reduce the global burden of infertility.
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